U.S. Entertainment Stock News

NasdaqGS:CSCO
NasdaqGS:CSCOCommunications

Is Cisco Systems (CSCO) Pricing Reflect Its Cash Flow And Earnings Potential?

If you are wondering whether Cisco Systems' current share price lines up with its underlying worth, this article walks through what the numbers are saying about value. Over shorter periods the stock has been choppy, with a 1.6% decline over the last 7 days and an 8.4% decline over the last 30 days, set against a 2.2% year to date return, 31.2% return over 1 year, 72.5% over 3 years and 80.8% over 5 years. Recent coverage has focused on Cisco Systems' role as a major networking and...
NasdaqGS:WBD
NasdaqGS:WBDEntertainment

Paramount Skydance WBD Deal Tests Streaming Synergies And AI Ambitions

Paramount Skydance has reached a landmark agreement to acquire Warner Bros. Discovery (NasdaqGS:WBD). The deal combines major film and TV studios, along with extensive content libraries and franchises, under a single owner. Management plans include merging HBO Max with Paramount+, cutting costs across overlapping operations, and building an AI focused content production model. The transaction follows a competitive bidding process in which Netflix exited and received a breakup fee. For you...
NYSE:UWMC
NYSE:UWMCDiversified Financial

Raised 2026 Revenue Guidance and AI Push Might Change The Case For Investing In UWM Holdings (UWMC)

In February 2026, UWM Holdings reported fourth-quarter 2025 net income of US$19.41 million, reaffirmed a US$0.10 per-share dividend payable in April 2026, and issued first-quarter 2026 revenue guidance initially in the US$650 million–US$850 million range, later updated to US$800 million–US$900 million alongside full-year 2026 guidance of US$3.5 billion–US$4.5 billion. An interesting development is UWM’s emphasis on AI-driven efficiency, with tools like its Mia voice assistant expected to...
NYSE:TAP
NYSE:TAPBeverage

Is Molson Coors (TAP) Offering Quiet Value After Its Recent Share Price Slide

If you are wondering whether Molson Coors Beverage shares are pricing in too much pessimism or offering quiet value, this is a good moment to take a closer look. The stock recently closed at US$45.87, with returns of a 4.6% decline over 7 days, an 11.4% decline over 30 days, a 3.2% decline year to date, a 21.0% decline over 1 year, and a 2.5% decline over 3 years, compared with a 10.0% gain over 5 years, which may have changed how investors see its risk and potential. Recent coverage of...
NYSE:PATH
NYSE:PATHSoftware

Should UiPath’s New Agentic AI Offerings and AIUC-1 Certification Require Action From UiPath (PATH) Investors?

UiPath, Inc. recently launched agentic AI automation solutions for healthcare revenue cycle management and financial crime compliance, while also securing AIUC-1 certification for secure AI agents. These product launches and certifications arrive just after UiPath’s fiscal Q4 2026 earnings release, drawing attention to how AI-driven automation may influence its long-term growth profile. We’ll now examine how UiPath’s healthcare-focused agentic AI launch could influence the company’s broader...
NYSE:FIG
NYSE:FIGSoftware

Figma (FIG) Valuation Check After Recent Share Price Pullback And Mixed Short Term Returns

Figma stock snapshot after recent trading moves Figma (FIG) has drawn fresh attention after a recent pullback, with the share price closing at US$28.35 and short term returns mixed across the past week, month, and past 3 months. See our latest analysis for Figma. The recent 7 day share price return of 7.77% and 1 day decline of 6.99% come after a strong 30 day share price return of 28.92%. However, the year to date share price return of 24.62% and 90 day share price return of 27.79% indicate...
NYSE:FDS
NYSE:FDSCapital Markets

Is FactSet (FDS) Now At An Attractive Price After Recent Share Price Weakness

If you are wondering whether FactSet Research Systems is attractively priced or still looks expensive, this article will walk through what the numbers are really saying about its current valuation. The share price closed at US$212.01, with returns of a 4.9% decline over 7 days, 2.3% over 30 days, a 25.6% decline year to date, a 50.1% decline over 1 year, a 46.5% decline over 3 years, and a 29.9% decline over 5 years, which may have changed how investors view its risk and return...
NasdaqGS:ADI
NasdaqGS:ADISemiconductor

Analog Devices (ADI) Sees AI Data Center Orders Surge Is Its Automation Story Quietly Evolving?

In recent quarters, Analog Devices reported quarterly revenue growth of 30% and guided for record Q2 revenue of about US$3.50 billion, driven by broad industrial strength and surging AI data center demand. An interesting element of this update is management’s view that the upswing reflects genuine end-market demand rather than temporary channel restocking, underscoring the depth of industrial and AI-related orders. Next, we’ll examine how this surge in genuine AI data center demand may...
NYSE:SYY
NYSE:SYYConsumer Retailing

Is It Time To Reconsider Sysco (SYY) After Recent Share Price Pullback?

If you are wondering whether Sysco is priced fairly today or if there is still value left on the table, this article walks you through what the numbers are really saying about the stock. Sysco shares last closed at US$84.29, with returns of 16.1% year to date and 16.3% over the past year, despite a 4.2% decline over 7 days and a 2.6% decline over 30 days that may be shifting how some investors see the risk and reward balance. Recent coverage has focused on Sysco's position as a major...
NYSE:FCPT
NYSE:FCPTSpecialized REITs

Four Corners Expands Auto Service Portfolio With Indiana And Texas Deals

Four Corners Property Trust (NYSE:FCPT) has acquired automotive service properties in Texas and Indiana. Each property is operated under a long term triple net lease with a national automotive service tenant. The transactions extend FCPT’s reach beyond casual dining into essential, car focused retail locations. For you as an investor, these new deals highlight how Four Corners Property Trust, known for its net lease portfolio centered on restaurants, is adding more automotive service assets...
NasdaqGM:CHRS
NasdaqGM:CHRSBiotechs

Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses

Coherus Oncology (CHRS) just posted its FY 2025 numbers with Q4 revenue of US$12.7 million and a basic EPS loss of US$0.39, while trailing 12 month figures show revenue of US$42.2 million and a basic EPS loss of US$1.56. Over recent quarters, the company has seen revenue move from US$7.6 million in Q1 2025 to US$12.7 million in Q4 2025, with quarterly basic EPS losses in a tight band around US$0.38 to US$0.41. This keeps the focus squarely on how efficiently each extra dollar of sales is...
NasdaqGS:INVA
NasdaqGS:INVAPharmaceuticals

How Investors May Respond To Innoviva (INVA) Surging EPS From Continuing Operations

In February 2026, Innoviva, Inc. reported fourth-quarter 2025 revenue of US$114.61 million and net income of US$164.15 million, alongside full-year revenue of US$411.33 million and net income of US$271.17 million, all higher than the prior year. An interesting feature of this release is the sharp increase in basic earnings per share from continuing operations, with quarterly EPS rising to US$2.19 and full-year EPS reaching US$4.02 compared with the previous year. We’ll now explore how...
NasdaqGS:EXE
NasdaqGS:EXEOil and Gas

Is It Time To Reassess Expand Energy (EXE) After The Recent Share Price Pullback

If you are wondering whether Expand Energy at US$104.67 is still worth your attention or if most of the upside has already been priced in, this article breaks down what the current share price might be implying about value. The stock has recently seen a 3.1% decline over 7 days and is down 5.2% over 30 days, even though the 1-year return sits at 7.6% and the 5-year return is a very large gain of around 2x. Recent coverage around Expand Energy has focused on its position within the energy...
NasdaqGS:BMRN
NasdaqGS:BMRNBiotechs

PALYNZIQ Pediatric Label Expansion Under REMS Might Change The Case For Investing In BioMarin (BMRN)

BioMarin Pharmaceutical Inc. recently received FDA approval for a supplemental Biologics License Application expanding PALYNZIQ (pegvaliase-pqpz) use to pediatric phenylketonuria patients aged 12 and older, based on PEGASUS Phase 3 safety and efficacy data. This approval broadens PALYNZIQ’s eligible patient population but comes with a REMS restriction due to immune-mediated risks including anaphylaxis, highlighting both opportunity and safety management demands for BioMarin. We’ll now...
NYSE:ETN
NYSE:ETNElectrical

Eaton’s SPAN Smart-Panel Bet Might Change The Case For Investing In Eaton (ETN)

In early March 2026, Eaton announced a partnership with SPAN, investing US$75,000,000 to co-develop smart electrical panels that support affordable home electrification and reduce grid infrastructure needs, with joint solutions targeted for release in the second quarter of 2026. This move extends Eaton’s “Home as a Grid” approach by pairing its distribution and protection hardware with SPAN’s energy intelligence software, potentially deepening Eaton’s role in managing household energy use...
NYSE:BUR
NYSE:BURDiversified Financial

A Look At Burford Capital’s Valuation After Q4 2025 Earnings, Insider Buying And New Buyback Program

Burford Capital (NYSE:BUR) has been in focus after its Q4 2025 earnings showed lower revenue, a quarterly net loss, and reduced earnings per share, alongside insider share purchases and a new repurchase program. See our latest analysis for Burford Capital. At a share price of US$8.28, Burford Capital has had a softer run recently, with a 30 day share price return of 7.17% and a year to date share price return of 5.37%. The 1 year total shareholder return of a 36.94% decline contrasts with...
NYSE:CW
NYSE:CWAerospace & Defense

Curtiss-Wright (CW) Valuation Check After New Aerospace Partnership And Defense Contract Wins

What the recent aerospace deals tell you about Curtiss-Wright Curtiss-Wright (CW) has been in focus after two recent aerospace and defense wins: a new partnership with Averna to build custom aerospace test systems and a four year U.S. Department of Defense contract for helicopter support equipment. See our latest analysis for Curtiss-Wright. The recent Averna partnership and U.S. Department of Defense contract arrive as Curtiss-Wright’s share price trades at US$703.61, with a 30-day share...
NYSE:RCUS
NYSE:RCUSBiotechs

Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion

Arcus Biosciences recently reported full-year 2025 results, with revenue of US$247 million versus US$258 million in 2024 and a net loss of US$353 million, while also granting new employee equity awards under its 2020 Inducement Plan. More importantly for the story, Arcus outlined encouraging new clinical data and expansion plans for its HIF-2α inhibitor casdatifan in kidney cancer, alongside moves into inflammatory and autoimmune diseases that could reshape how investors view its pipeline...
NYSE:JEF
NYSE:JEFCapital Markets

Does Jefferies (JEF) Face a Credibility Test as Legal Scrutiny Meets Ongoing Debt Issuance Strategy?

In early March 2026, Western Alliance Bancorporation sued Jefferies Financial Group over a US$126.4 million commercial loan tied to allegedly fraudulent First Brands Group receivables, while Jefferies simultaneously continued issuing long-dated senior unsecured notes across multiple fixed-income offerings. Jefferies has firmly rejected Western Alliance’s claims, highlighting the non-recourse structure of the disputed loans and disclosing related regulatory and legal scrutiny, including an...
NYSE:BVN
NYSE:BVNMetals and Mining

A Look At Compañía de Minas Buenaventura (BVN) Valuation After Strong Earnings And Proposed Dividend

Compañía de Minas BuenaventuraA (BVN) has put income and earnings in focus after its board proposed a US$0.9904 per share dividend, alongside detailed fourth quarter and full year 2025 results. See our latest analysis for Compañía de Minas BuenaventuraA. Those earnings and dividend headlines come after a very strong run in the stock, with a 44.99% 90 day share price return, a 36.06% year to date share price return and a 1 year total shareholder return of 192.62%. This suggests momentum has...
NasdaqGS:FTNT
NasdaqGS:FTNTSoftware

Assessing Fortinet (FTNT) Valuation After Recent Share Price Gains And Mixed Earnings Signals

Context for Fortinet after recent performance Fortinet (FTNT) continues to draw attention after recent share price moves, with a 1 day return of 0.5%, about 3.8% over the past week and a modest gain over the past month. Investors are also weighing its roughly 3.2% return over the past 3 months and 8.1% year to date, against a 14.3% negative 1 year total return and longer term gains over 3 and 5 years. See our latest analysis for Fortinet. At a share price of $84.20, Fortinet’s recent positive...
NYSE:TMO
NYSE:TMOLife Sciences

Is Thermo Fisher Scientific (TMO) Fairly Priced After Recent Share Price Weakness?

If you are wondering whether Thermo Fisher Scientific at around US$500 per share still offers solid value, this article will walk through what the current price really implies. The stock is currently around US$500.08, with returns of a 1.6% decline over 7 days, 7.9% decline over 30 days, 15.6% decline year to date, 2.4% decline over 1 year and 9.3% decline over 3 years, while the 5 year return sits at 13.4%. Recent news coverage has focused on Thermo Fisher Scientific's role as a key...
NYSE:NEE
NYSE:NEEElectric Utilities

A Look At NextEra Energy (NEE) Valuation After Chief Risk Officer Resignation Uncertainty

NextEra Energy (NEE) is back in focus after chief risk officer Terrell Kirk Crews II announced his resignation, effective March 20, 2026, leaving investors weighing what this means for risk oversight. See our latest analysis for NextEra Energy. Recent events, including the chief risk officer’s planned exit and a US$2b composite units offering, have come against a backdrop of building momentum. The 30 day share price return of 2.31% and the 90 day share price return of 12.64%, alongside the 1...
NasdaqGS:TLRY
NasdaqGS:TLRYPharmaceuticals

Tilray’s BrewDog Australia Deal Expands Asia Pacific Reach Amid Weak Shares

Tilray Brands has completed its acquisition of BrewDog Brewing Australia, expanding its beverage platform into the Asia Pacific region. The deal adds an Australian production facility, bar network, and new distribution channels to Tilray’s existing BrewDog UK relationship. This move is described by the company as its most significant international step in beverages so far. Tilray Brands, traded as NasdaqGS:TLRY, now pairs its existing BrewDog UK exposure with a direct operating footprint in...